Tumor indicators related to breast cancer Ca153:cancer antigen 153 Normal range: <25iu/ml Zhong Shaowen, Department of Breast Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine Ca125:cancer antigen 125 Normal range: <35iu/ml CEA:carcinoembryonic antigen Normal range: <5ng/ml TPA:tissue peptide antigen Normal range: <1.2ng/ml CA153 1. The specificity of CA153 can be 87%, but its sensitivity is only 69%. 2.It is used to observe whether there is recurrence after treatment and to detect metastasis of breast cancer. 3.It can also be elevated in varying degrees in bronchial cancer and pregnancy. CA125 1.The index has a certain positive response in breast cancer patients. Its specificity can reach 84%, but its sensitivity is only 32.4%. CEA 1, can be seen in various adenocarcinomas (breast, gastrointestinal tract, lung), 60% of breast cancer patients have significantly elevated CEA, often exceeding 60 /ml; 2, breast cancer, its specificity can reach 90.2%, but its sensitivity is only 16.7%. In conclusion, if combined with CA153, CA125 and CEA, the sensitivity can reach 85.6% and specificity up to 96.4%. All tumor markers are not absolute, one tumor may release several tumor markers at the same time, and one tumor marker may appear in many different tumors, malignant tumors other than breast cancer, or even some benign diseases, these markers can be elevated. High tumor markers do not necessarily change the treatment plan. 1. For patients with advanced breast cancer, changes in tumor markers alone cannot be used as a basis for changing treatment, because current studies have shown that tumor markers alone do not affect overall survival time. 2. 2. For patients with diagnosed breast cancer, the dynamic changes of these indicators can indicate the progression of the disease and assess the effectiveness of treatment by detecting them. 3. For mildly elevated tumor markers, pay attention to continuous monitoring for continuous elevation and the degree of elevation. And check regularly for the presence of new lesions.